Today's Rundown Featured Story | Thursday, April 23, 2020 The World Health Organization accidentally revealed data from a study in China showing that the treatment neither improved patients’ condition nor tamped down on the amount of virus in their blood, the Financial Times reported, calling the trial a “flop.” But was it really a flop? |
|
---|
|
Top Stories Friday, April 24, 2020 Sanofi is culling a Regeneron-partnered med and still looking for partners for two unwanted pipeline candidates as the Big Pharma continues to reshuffle its R&D priorities. Friday, April 24, 2020 ORIC Pharma is the latest biotech to go public since the World Health Organization declared COVID-19 a pandemic. The cancer biotech priced its IPO at the top end of its range, raking in $120 million and eclipsing its $86 million goal. Friday, April 24, 2020 GlaxoSmithKline has posted some updated though underwhelming and “clinically meaningful” data from a PD-1 inhibitor it got via its $5 billion Tesaro buyout. Friday, April 24, 2020 Takeda has allied with ProThera Biologics to develop a plasma-derived inter-alpha inhibitor proteins (IAIP) therapy for use in acute inflammatory conditions. The deal advances Takeda’s efforts to extract value from the plasma-derived therapy unit it acquired in its $62 billion takeover of Shire. Friday, April 24, 2020 Researchers at UT Southwestern Medical Center discovered that a protein called calcineurin plays a key role in blocking the ability of heart muscle to regenerate after the first week of life. The finding could be used to develop treatments that reverse this process, offering new strategies for repairing hearts damaged by heart attacks, high blood pressure, viruses and more, they said. Thursday, April 23, 2020 As hospitals redirect resources toward COVID-19 and patients put off less-urgent medical procedures and trips to the doctor, Medtronic has seen serious impacts on its bottom line—including a 60% drop in weekly revenue from the U.S., where the medtech giant does most of its business. Friday, April 24, 2020 A leaked document suggested Gilead's remdesivir fell short in a Chinese trial in severe COVID-19 patients. A key pharma manufacturing hub in India is suffering from lower capacity due to a local lockdown. Samsung Bioepis has launched its Herceptin biosimilar in the U.S. at a 15% discount. And more. Friday, April 24, 2020 Silverback nabs Synthorx vet Shawver as CEO; PTC brings Klein aboard as CDO; deposed BARDA chief Bright calls out Trump administration. Resources Sponsored by: Blue Latitude Health Report: Think you’re patient-centric? Think again. Find out how patients really feel about patient-centricity. Learn what they would like to experience along with tools and tips for maximising patient engagement across the product life cycle¬ – from clinical trials to service design and creative campaigns. Sponsored by: BBK Worldwide Leverage strategic solutions to respond to immediate challenges to patient and site engagement from COVID-19, and learn to maximize the FDA guidance on the conduct of clinical trials during a pandemic. Sponsored by: Oracle Health Sciences The research conducted here is to help understand and solve the top challenges in clinical operations, to remove barriers that are slowing down our ability to bring new drugs to market as quickly as possible to patients waiting in need. Sponsored by: Clinical Ink This white paper includes a Phase III case study and discusses BYOD advantages and misconceptions, regulatory, copyright, and equivalency considerations. Sponsored by: Research Solutions Turn your drug failures into competitive advantage. Sponsored by: ICON How will US payers evaluate and manage digital therapeutics? Get insights and recommendations on successful market access considerations. Sponsored by: Copyright Clearance Center Despite advances in content aggregation and search, silos still limit the free flow of data and analytics. So, what can be done, and how can you get more value from the data you already have? Sponsored by: Applied BioMath Learn how we used a tiered model-based approach of a bispecific antibody to appropriately cover multiple antigen pairs to help teams with informed antibody design, prioritization of experiments, and triaging of challenging antigen pairs Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Outer Edge Technology To survive in these challenging conditions, companies need to promptly address business continuity issues - especially the remote delivery of data and voice solutions. See how Outer Edge can help. Sponsored by: Patheon, by Thermo Fisher Scientific Poorly soluble molecules hindering your workflow? Sponsored by: eClinical Solutions Key findings from the 2019 Life Sciences Data & Analytics Survey conducted by the Tufts Center for the Study of Drug Development will be unveiled during this live webinar led by industry expert and study lead, Ken Getz, Director of Sponsored Programs and Associate Professor. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent This whitepaper discusses the benefits of end-to-end solutions and share case studies on how flexible manufacturing strategies can accommodate the changing landscape of pharmaceutical products and help bring a drug to market. Sponsored by: Catalent Get expert insights on strategies to implement flexible manufacturing and different technologies that are easily scalable and reproducible. Sponsored by: Catalent Regardless of the assigned FDA expedited approval designation and approach, the key action items should be: the assurance of a detail-oriented plan and the adaption of a “forward-thinking” approach that will assist in any future challenges and opportunities for growth of each project. Sponsored by: Clarify Health Pharma launch teams spend significant resources on data and analytics with limited ROI. Read this case study to learn how a Life Sciences company identified two times more patients best suited for therapy, using Clarify’s deep and longitudinal patient and HCP insights. |